STOCK TITAN

Cytek Biosciences (CTKB) Stock News

CTKB NASDAQ

Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.

News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.

Rhea-AI Summary

Cytek Biosciences (CTKB) will participate in two investor conferences, with CEO Wenbin Jiang and CFO William McCombe attending both. They will join investor meetings at Evercore’s 9th Annual Healthcare Conference in Miami on December 1, 2026. They will also hold investor meetings at Piper Sandler’s 38th Annual Healthcare Conference in New York on December 2, 2026, and join a webcast fireside chat at 4:30 p.m. Eastern Time that day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.76%
Tags
conferences
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) received the Drug Discovery Innovation of the Year award for its Aurora Evo system in the 2026 BioTech Breakthrough Awards.

The system uses spectral flow cytometry to analyze samples. For workflows using plate wells, acquisition time has been reduced by approximately 40% compared with earlier generations. It includes automated startup and shutdown and instrument harmonization to support consistent results across laboratories. Cytek is also developing the platform to provide a path toward automated sample processing using robotic arms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
none
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) reported third-quarter 2026 revenue of $53.2 million, up 2% from the same quarter last year. GAAP gross margin rose to 59% from 53%, while operating loss narrowed to $8.4 million from $9.2 million. Net loss widened to $6.1 million, or $0.05 per share, from $5.5 million, or $0.04 per share.

Recurring service and reagent revenue reached $19.1 million; its trailing-12-month share of revenue increased to 36% from 33%. Adjusted EBITDA fell to $0.7 million from $2.5 million. Cash, restricted cash and marketable securities totaled $256.3 million, down $5.7 million from June 30, 2026. Cytek maintained its full-year revenue outlook midpoint and narrowed the range to $208 million–$211 million, assuming unchanged exchange rates. An August jury verdict favored Cytek on three asserted patent claims but found infringement under the doctrine of equivalents on a fourth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
Rhea-AI Summary

Cytek Biosciences (CTKB) will participate in the UBS Global Healthcare Conference and Stephens Annual Investment Conference in November 2026.

CFO William McCombe and Head of Investor Relations Mark Meehan will hold investor meetings in Palm Beach Gardens on November 9. CEO Wenbin Jiang and McCombe will join a fireside chat in Nashville on November 17 at 6:00 a.m. Pacific / 9:00 a.m. Eastern. A live and archived Stephens webcast will be available on the company’s investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.70%
Tags
conferences
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) will report third-quarter 2026 financial results after market close on November 4, 2026. Management will discuss results, business developments and outlook on a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern that day. A live audio webcast will be available in the Investors section at investors.cytekbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
earnings date
-
Rhea-AI Summary

Cytek Biosciences (CTKB) announced the addition of Cloud Analysis to its Cytek Cloud platform on September 23, 2026.

The tool imports experimental data directly from SpectroFlo desktop software, allowing researchers to continue analysis where they left off. It also provides online storage and access from a Mac or PC. Cytek Cloud has more than 28,000 users and double-digit year-over-year user growth.

Cytek also introduced a Premium subscription tier that adds Cloud Analysis and online storage to Pro features. Premium and the new analysis tool are currently available only in the U.S. The Basic plan provides core tools at no cost.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Rhea-AI Summary

Cytek Biosciences (CTKB) and Sysmex Europe announced a strategic collaboration across more than a dozen European countries to enhance clinical flow cytometry workflows. The partners aim to provide laboratories with an integrated, end-to-end solution spanning automated sample preparation, routine testing and advanced multi-color spectral analysis. Sysmex contributes its clinical flow portfolio, including the XF-1600 flow cytometer and PS-10 automated sample preparation system, while Cytek adds its Northern Lights™-CLC spectral flow cytometer. The combined offering targets complex applications such as leukemia, lymphoma and measurable residual disease assessment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Summary

Cytek Biosciences (CTKB) will highlight its spectral flow cytometry solutions and Full Spectrum Profiling™ (FSP®) technology at the ESCCA 2026 Conference and ICCS 2026 meeting this fall. These events focus on clinical cytometry applications across hematology, immunology, oncology, and broader clinical research.

Cytek’s spectral technology captures the full spectrum of fluorescent signals, allowing laboratories to design more complex panels, streamline workflows, and gain deeper insights from each sample. More than 4,200 peer-reviewed publications have cited Cytek FSP systems, underscoring their use in cell biology, immunology, oncology, and clinical research.

At ESCCA 2026 in Salzburg, Austria (September 9–12), Cytek will exhibit at Booth PL2 and host an Industrial Partner Presentation on September 11 at 12:15 p.m., led by Mikael Roussel, M.D., Ph.D., on the use of spectral cytometry in routine diagnostics and minimal residual disease (MRD) monitoring. At ICCS 2026 in Miami, Florida (October 2–6), Cytek will exhibit at Booths 100/101 and host a Corporate Workshop on October 4 at 2:00 p.m., as well as KOL dinners at both meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) announced participation in three upcoming healthcare investor conferences in September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference on September 8, the Morgan Stanley 24th Annual Global Healthcare Conference with a fireside chat on September 16, and Deutsche Bank’s 2026 Healthcare Summit on September 17.

According to Cytek Biosciences, CEO Wenbin Jiang and CFO William McCombe will join select sessions, and a live and archived webcast of the Morgan Stanley fireside chat will be available via the investors section of the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) reported that a Delaware jury returned a mixed verdict in a patent infringement case brought by Beckman Coulter. The jury found in Cytek’s favor on three of four asserted patent claims, determining noninfringement and invalidity for those claims.

For the remaining claim, the jury found no literal infringement but concluded infringement under the doctrine of equivalents and awarded past damages of $20 million in lost profits and $36 million in royalties. Cytek plans post-verdict motions to challenge this finding and the damages, and stated that the verdict does not require changes to its current products, which remain available worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none

FAQ

What is the current stock price of Cytek Biosciences (CTKB)?

Cytek Biosciences (CTKB) last closed at $6.12.

What is the market cap of Cytek Biosciences (CTKB)?

The market cap of Cytek Biosciences (CTKB) is approximately $800.4M.